Goldman Sachs Group Inc set a GBX 3,900 ($48.17) target price on AstraZeneca plc (LON:AZN) in a report published on Thursday. The brokerage currently has a sell rating on the biopharmaceutical company’s stock.

Other equities research analysts also recently issued research reports about the stock. Bryan, Garnier & Co restated a buy rating and issued a GBX 5,100 ($62.99) price objective on shares of AstraZeneca plc in a research note on Tuesday, November 22nd. Berenberg Bank lowered their price objective on shares of AstraZeneca plc from GBX 5,550 ($68.54) to GBX 5,500 ($67.93) and set a buy rating on the stock in a research note on Thursday, November 17th. Societe Generale restated a buy rating and issued a GBX 6,500 ($80.28) price objective on shares of AstraZeneca plc in a research note on Wednesday, November 16th. Deutsche Bank AG restated a buy rating and issued a GBX 6,000 ($74.10) price objective on shares of AstraZeneca plc in a research note on Wednesday, November 30th. Finally, Jefferies Group LLC restated a buy rating and issued a GBX 5,400 ($66.69) price objective (down previously from GBX 5,600 ($69.16)) on shares of AstraZeneca plc in a research note on Monday, December 19th. Four research analysts have rated the stock with a sell rating, eight have given a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. The company has an average rating of Hold and a consensus price target of GBX 5,018.36 ($61.98).

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Shares of AstraZeneca plc (LON:AZN) opened at 4871.50 on Thursday. The firm’s market capitalization is GBX 61.64 billion. AstraZeneca plc has a 12-month low of GBX 3,680.00 and a 12-month high of GBX 5,505.00. The company has a 50-day moving average of GBX 4,617.49 and a 200 day moving average of GBX 4,602.58.

Your IP Address:

The firm also recently declared a dividend, which was paid on Monday, March 20th. Investors of record on Thursday, February 16th were issued a GBX 150.20 ($1.86) dividend. This represents a dividend yield of 3.52%. This is a boost from AstraZeneca plc’s previous dividend of $68.70. The ex-dividend date was Thursday, February 16th.

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.

Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.